Psych Flashcards
name SSRIs
sertraline
fluoxetine
citalopram
name SNRIs
venlafaxine
duloxetine
name NASSAs
noradrenergic and specific serotenergic antidepressants
mirtazepine (old + frail)
name NARI
ruboxetine
list TCAs
amitriptyline
clomipramine
nortryptiline
list MAOi
phenelzine
selegiline
name a RIMA
reversible inhibitors of monoamine oxidase
moclobemide
list typical antipsychotics
chlorpromazine
haloperidol
flupentixol decanoate
list atypical antipsychotics
olanzapine respiridone quetiapine aripiprazole clozapine amisulpride
mild/moderate/severe depression
mild - 2/3 core + at least 2 others - normal life
moderate - 2/3 core + at least 3/4 others - difficulty with normal life
severe - 3 core + at least 4 others - marked functional impairment
PHQ9 scale
GP rate 0-3 0 = none 5 = mild 10 = mod >15 = severe
HADS scale
rate 0-3
0-7 = normal
8-10 = borderline
11-21 = abnormal
CDI
childrens depression index
medication steps in depression
SSRI trial another SSRI SNRI augment with antipsychotic (quetiapine)/ lithium ECT
symptoms of serotonin syndrome
ABRUPT
mental status change: agitation, confusion, coma
NM change: jerking, twitching, hyperreflexia
autonomic instability: hyperthermia, labile BP, tachycardia, sweating, dilated pupils, diarrhoea
treatment for SS
stop drug
bentos eg clonazepam
MOA of NASSA
presynaptic alpha 2 blockade - high noradrenaline and serotonin
recurrent depressive disorder
at least 1 previous episode lasting minimum 2 w
separated from current episode by at least 2 months
psychotic symptoms in BPAD
grandiose delusions
persecutory
auditory hallucinations
cyclothymia
persistent mood instability
does not meet criteria for depression/ BPAD
lithium side effects
fine tremor n+v nephrogenic DI arrhythmia hypothyroidism weight gain eyebrow hair loss
lithium toxicity symptoms
coarse tremor
hyperreflexia
nystagmus
seizures
side effects of sodium valproate
n+v diarrhoea liver failure thrombocytopenia hair loss weight gain
side effects of carbamazepine
(enzyme inducer) rash leukopenia dizziiness drowsiness n+v oedema weight gain hyponatraemia
bipolar depression
fluoxetine + atypical antipsychotic eg olanzapine
schizophrenia theories
+ve symptoms - excess dopamine in mesolimbic
-ve symptoms - dopamine under activity in mesocortiyal
stages of schizophrenia
1 - at risk mental state
2 - acute phase (+ve symptoms) - auditory hallucinations and persecutory delusions, loosening of associations, FTD
3 - chronic phase (-ve symptoms)
types of schizophrenia
paranoid - most common, d+h
catatonic - psychomotor disturbance, stupor, posturing, waxy flexibility, perseveration
hebephrenic - 15-25 yrs - disorganised chaotic mood
simple - negative only
(residual - mainly +ve symptoms)
schneiders 1st rank symptoms
passivity
auditory hallucinations - echo, 3rd person, running comm.
delusional perception
delusions of though interference
PADD
diagnostic criteria for schizophrenia
1st rank symptoms + >/=2 of…
- paranoid, hebephrenic, catatonic, simple
+ present most of the time >/= 1 month
+ not caused by substance use/ organic cause
(<1 mo = brief psychotic disorder)
impact on social/occupational functioning >6 mo
treatment for EPSE
Dystonia - procyclidine
Akathisia - lower dose, propranolol
Parkinsonism* - lower dose procyclidine
Tardive dyskinesia - reduce dose, avoid anticholinergics
- resting tremor, rigidity, bradykinesia
antipsychotics side effects
hyperprolactinaemia - respiridone weight gain (o+c) diabetes dyslipidaemia antichoninergic S/E NMS - haloperidol arrhythmias - prolonged QT - quetiapine stroke + VTE in elderly
symptoms of NMS
gradual
mental state changes: catatonia
muscular rigidity
autonomic instability - hyperthermia, labile BP, tachycardia, sweating
blood changes in NMS
High CK high WCC AKI high hepatic transaminases (due to low dopamine) death due to renal failure secondary to rhabdomylosis
NMS treatment
stop dose
dantrolene - muscle relaxant
bromocriptine - dopamine agonist